Roche Holding - Priority FDA review for breast cancer drug giredestrant
18.06.2026 - 21:06:51 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 20:55 CET. Details in the imprint.
Roche Holding (CH0012032048) has secured US FDA acceptance of its New Drug Application for giredestrant in early breast cancer under Priority Review. The move, disclosed in a recent company update cited by specialist news services, adds a clearly dated catalyst to Roche’s oncology pipeline.
All news and data on Roche Holding stock
Track corporate announcements, pipeline updates and price data for Roche Holding in one place via our curated topic overview.
FDA priority review as fresh catalyst
According to an aggregation of recent company communications, the US Food and Drug Administration has accepted Roche’s New Drug Application for giredestrant, an oral selective estrogen receptor degrader, for adults with ER-positive, HER2-negative stage I-III breast cancer under Priority Review. This status typically shortens the FDA review clock to around six months for therapies that may offer significant benefits over existing options.
The application covers adjuvant treatment following surgery in patients at elevated risk of recurrence, positioning giredestrant directly against a new wave of oral SERDs in development. While Roche has not yet disclosed a target FDA action date in its calendar, the Priority Review designation sets up a clear regulatory inflection point within the coming months.
Chart picture and upcoming earnings
Roche’s participation certificates on SIX Swiss Exchange recently traded in the low-to-mid CHF 320s, with intraday levels around CHF 323-327 cited in current market data. On balance, that keeps the stock in a broad sideways range seen in recent weeks, after previous sessions around the mid-CHF 320s.
Beyond the giredestrant news, the next firm date in the company’s financial diary is the half-year 2026 results presentation, scheduled as a virtual event for 07/23/2026 in the investor relations calendar. That date will give investors a new read on prescription trends, diagnostics demand and any updated commentary around the oncology pipeline.
What the company sells
Roche Holding AG generates most of its revenue from prescription medicines in oncology, immunology and hematology, alongside a significant diagnostics division spanning central laboratory systems, molecular diagnostics and point-of-care testing. Flagship oncology brands such as Avastin, Perjeta and Tecentriq remain important, even as newer targeted and immunotherapy agents expand the portfolio.
Where the stock trades today
The shares of Roche Holding (CH0012032048) trade on SIX Swiss Exchange at CHF 323.30 as of 06/18/2026, 17:30 CET.
Key facts on Roche Holding stock
- Company: Roche Holding AG
- ISIN: CH0012032048
- WKN: 851311
- Ticker: ROG
- Venue: SIX Swiss Exchange
- Price (as of 06/18/2026, 17:30 CET): 323.30 CHF
- Market cap: 262,550,000,000 CHF (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: SMI, Stoxx Europe 600
- Next earnings date: 07/23/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
